Amgen's Imlygic 1st FDA-Approved Oncolytic Virus Therapy
This article was originally published in Scrip
Executive Summary
Amgen Inc. made history on Oct. 27 by gaining the FDA's approval for the first oncolytic virus therapy – Imlygic (talimogene laherparepvec), which is indicated as a local treatment of unresectable cutaneous, subcutaneous and nodal lesions in patients with melanoma recurrent after initial surgery.